Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

MKB Parmar; M Adams; M Balestrino; K Bertelsen; C Bonazzi; H Calvert; N Colombo; JF Delaloye; A Durando; D Guthrie; B Hagen; P Harper; C Mangioni; T Perren; Christopher Poole; W Qian; G Rustin; Josie Sandercock; S Tumolo; V Torri; F Vecchione

doi:10.1016/S0140-6736(02)09738-6

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

MKB Parmar, M Adams, M Balestrino, K Bertelsen, C Bonazzi, H Calvert, N Colombo, JF Delaloye, A Durando, D Guthrie, B Hagen, P Harper, C Mangioni, T Perren, Christopher Poole, W Qian, G Rustin, Josie Sandercock, S Tumolo, V TorriF Vecchione

Research output: Contribution to journal › Article

466 Citations (Scopus)

Original language	English
Pages (from-to)	505-515
Number of pages	11
Journal	Lancet
Volume	360
Issue number	9332
DOIs	https://doi.org/10.1016/S0140-6736(02)09738-6
Publication status	Published - 17 Aug 2002

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(02)09738-6

Cite this

Parmar, MKB., Adams, M., Balestrino, M., Bertelsen, K., Bonazzi, C., Calvert, H., Colombo, N., Delaloye, JF., Durando, A., Guthrie, D., Hagen, B., Harper, P., Mangioni, C., Perren, T., Poole, C., Qian, W., Rustin, G., Sandercock, J., Tumolo, S., ... Vecchione, F. (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet, 360(9332), 505-515. https://doi.org/10.1016/S0140-6736(02)09738-6

@article{73d9d7e221434d50a2644bbf093026cb,

title = "Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial",

author = "MKB Parmar and M Adams and M Balestrino and K Bertelsen and C Bonazzi and H Calvert and N Colombo and JF Delaloye and A Durando and D Guthrie and B Hagen and P Harper and C Mangioni and T Perren and Christopher Poole and W Qian and G Rustin and Josie Sandercock and S Tumolo and V Torri and F Vecchione",

year = "2002",

month = aug,

day = "17",

doi = "10.1016/S0140-6736(02)09738-6",

language = "English",

volume = "360",

pages = "505--515",

journal = "Lancet",

issn = "1474-547X",

publisher = "Elsevier",

number = "9332",

}

Parmar, MKB, Adams, M, Balestrino, M, Bertelsen, K, Bonazzi, C, Calvert, H, Colombo, N, Delaloye, JF, Durando, A, Guthrie, D, Hagen, B, Harper, P, Mangioni, C, Perren, T, Poole, C, Qian, W, Rustin, G, Sandercock, J, Tumolo, S, Torri, V & Vecchione, F 2002, 'Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial', Lancet, vol. 360, no. 9332, pp. 505-515. https://doi.org/10.1016/S0140-6736(02)09738-6

TY - JOUR

T1 - Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

AU - Parmar, MKB

AU - Adams, M

AU - Balestrino, M

AU - Bertelsen, K

AU - Bonazzi, C

AU - Calvert, H

AU - Colombo, N

AU - Delaloye, JF

AU - Durando, A

AU - Guthrie, D

AU - Hagen, B

AU - Harper, P

AU - Mangioni, C

AU - Perren, T

AU - Poole, Christopher

AU - Qian, W

AU - Rustin, G

AU - Sandercock, Josie

AU - Tumolo, S

AU - Torri, V

AU - Vecchione, F

PY - 2002/8/17

Y1 - 2002/8/17

U2 - 10.1016/S0140-6736(02)09738-6

DO - 10.1016/S0140-6736(02)09738-6

M3 - Article

SN - 1474-547X

VL - 360

SP - 505

EP - 515

JO - Lancet

JF - Lancet

IS - 9332

ER -